Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Inactivation or attenuation; producing viral subunits
Reexamination Certificate
2003-09-22
2010-06-01
Parkin, Jeffrey S. (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
Inactivation or attenuation; producing viral subunits
C435S238000, C424S207100
Reexamination Certificate
active
07727757
ABSTRACT:
Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation. The inactivated virus may be more safely handled, stored, and analyzed, used in diagnostic procedures and kits, and may be used as an immunogen to evoke an immune response. The immune response may protect an individual from challenges with live virus. Alternatively, the inactivated HIV particles may be used to augment the immune response to HIV in an infected individual.
REFERENCES:
patent: 5849475 (1998-12-01), Rovinski et al.
patent: 5919458 (1999-07-01), Aldovini et al.
patent: 6017543 (2000-01-01), Salk et al.
patent: 6080408 (2000-06-01), Rovinski et al.
patent: 6383806 (2002-05-01), Rios
Ferrari, G., et al., 1997, Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers, Proc. Natl. Acad. Sci. USA, 94: 1396-1401.
Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet 366:1894-1898.
Wang, L.-X., 2003, Bioorganic approaches towards HIV vaccine desgin, Cur. Pharm. Design, 2003, 9:1771-1787.
Walker, B. D., and D. R. Burton, 2008, Toward an AIDS vaccine, Science 320:760-764.
Boeke, “The Unusual Phylogenetic Distribution of Retrotransposons: A Hypothesis,”Genome Res., 13:1975-1983, 2003.
Flavell, “Retroelements, reverse transcriptase and evolution,”Comp. Biochem. Physiol., 110B:3-15, 1995.
Lingner et al., “Reverse Transcriptase Motifs in Catalytic Subunit of Telomerase,”Science, 276:561-567, 1997.
Lundblad, “Telomerase catalysis: A phylogenetically conserved reverse transcriptase,”Proc. Natl. Acad. Sci. USA, 95:8415-8416, 1998.
Nakamura et al., “Telomerase Catalytic Subunit Homologs from Fission Fission Yeast and Human,”Science, 277:955-959, 1997.
Seifarth et al., “Rapid Identification of All Known Retroviral Reveres Transcriptase Sequences with a Novel Versatile Detection Assay,”AIDS Research and Human Retrovirus, 16:721-729, 2000.
Springer and Britten, “Phylogenetic Relationships of Reverse Transcriptase and RNase H Sequences and Aspects of Genome Structure in the Gypsy Group of Retrotransposons,”Mol. Biol. Evol., 10:1370-1379, 1993.
Valverde-Garduno et al., “Functional analysis of HIV-1 reverse transcriptase motif C: site-directed mutagenesis and metal cation interaction,”J. Mol. Evol., 47:73-80, 1998 (abstract only).
Ada, “An Immunologist's View of HIV Infection,”Textbook of AIDS Medicine, Chapter 6, pp. 77-87, Brother et al., eds., Williams & Wilkens, Baltimore, MD, 1994.
Ada, “Modern vaccines, the immunological principles of vaccination,”The Lancet, 335:523-526, 1990.
Albert, et al., “Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs,”Nature, 392:86-89, 1998.
Aldrovandl et al., “The SCID-hu mouse as a model for HIV-1 infection,”Nature, 363:732-736, 1993.
Amadori et al., “The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats,”Semin Immunol, 8:249-254, 1996.
Baba et al., “Pathogenicity of live, attenuated hiv after mucosal infection of neonatal macaques,”Science, 267:1820-1825, 1995.
Bachmann and Zinkernagel, “Neutralizing antiviral b cell responses,”Annu. Rev. Immunol., 15:235-270, 1997.
Balter, “A cluster of Europe's aids research stars,”Science, 280:1862, 1998c.
Balter, “Duo brings hope of immune restoration,”Science, 280:1861, 1998b.
Balter, “Global program struggles to stem the flood of new cases,”Science, 280:1863-1864, 1998d.
Balter, “HIV incidence: ‘more serious than we imagined’,”Science, 280:1864, 1998e.
Balter, “Modest briton stirs up storm with views on role of CTLs,”Science, 280:1860-1861, 1998a.
Balter, “T cell production slowed, not exhausted?”Science, 283(5400):305-306, 1999.
Baltimore, “Lessons from people with nonprogressive hiv infection,”The New England J. of Medi., 332:259-260, 1995.
Banchereau and Steinman, “Dendritic cells and the control of immunity,”Nature, 392:245-252, 1998.
Barnard et al., “The thiocarboxanilide nonnucleoside uc781 is a tight-binding inhibitor of hiv-1 reverse transcriptase,”Biochem., 36:7786-7792, 1997.
Barr, “Vaccines for HIV, HIV therapeutic vaccines: the next phase,”GMHC's Treat. Iss., vol. 7, No. 5, 1993.
Bender et al., “Inactivated influenza virus, when presented on dendritic cells, elicits human cd8+cytolytic t cell responses,”J. Exp. Med., 12:1663-1671, 1995.
Berger et al., “A new classification of HIV-1,”Nature,391:340, 1998.
Blauvelt et al., “Productive infection of dendritic cells by hiv-1 and their ability to capture virus are mediated through separate pathways,”The J. of Clin. Invest., 100:2043-2053, 1997.
Bolognesi and Matthews, “Viral envelope fails to deliver?,”Nature, 391:638-639, 1998.
Bombil et al., “A promising model of primary human immunization inhuman-scid mouse,”Immunobiology, 195:360-375, 1996 (Abstract).
Borkow et al., “Chemical barriers to human immunodeficiency virus type 1 (hiv-1) infection: retrovirucidal activity of uc781, a thiocarboxanilide nonnucleoside inhibitor of hiv-1 reverse transcriptase,”J. of Virol., 71:3023-3030, 1997.
Borkow et al., “Chemical barriers to Human Immunodeficiency Virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor or HIV-1 reverse transcriptase,”Journal of Virology71(4):3023-3030, 1997.
Borkow et al., “Inhibition of the ribonuclease H and DNA polymerase activities of hiv-1 reverse transcriptase by n-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone,”Biochemistry, Abstract, 36(11):3179-3185, 1997.
Bryson et al., “Clearance of HIV infection in a perinatally infected infant,”The New Engl. J. of Med., 332:833-838, 1995.
Buckheit et al., “Efficacy pharmacokinetics and in vivo anti-HIV activity of the highly potent oxathiin carboxanilide analog, UC781,”Journal of Molecular Medicine75(7):b212-b213, 1997.
Buckheit et al., “Efficacy, Pharmacokinetics, and in Vivo Antiviral Activity of UC781, a Highly Potent, Orally Bioavailable Nonnucleoside Reverse Transcriptase Inhibitor of HIV Type 1,”Aids Res. and Hu. Retro., 13:789-796, 1997.
Burr, “Of AIDS and altruism,”U.S. Nws.&W. Rpt., pp. 59-61, Apr. 6, 1998.
Burton and Montefiori, “The antibody response in HIV-1 infection,”Aids, 11:S87-S98, 1997.
Cao et al., “Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection,”The New Engl. J. of Med., 332:201-216, 1995.
Carlson et al., “Vaccine Protection of Rhesus Macaques Against Simian Immunodeficiency Virus Infection,”AIDS Res. and Hum. Retroviruses, 6:1239-1246, 1990.
Cavert and Haase, “A national tissue bank to track HIV eradication and immune reconstitution,”Science, 280:1865-1866, 1998.
Cella et al., “Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells,”Nature, 388:782-792, 1997.
Chowdhry, “Photoaffinity labeling of biological systems,”Ann. Rev. Biochem., 48:293-325, 1979.
Clerici et al., “HIV-specific t-helper activity in seronegative health care workers exposed to contaminated blood,”JAMA, 271:42-46, 1994.
Clotet et al., “Long-term survivors of human immunodeficiency virus type I infection,”The New England Journal of Medicine, 332(24):1646-1647, 1995.
Cohen et al., “Characterization of the binding site for nevirapine (bi-rg-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase,”J. of Biol. Chem., 266:14670-14674, 1991.
Collins et
Fulbright & Jaworski LLP
Parkin Jeffrey S.
LandOfFree
Methods of eliciting antiviral immune responses utilizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of eliciting antiviral immune responses utilizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of eliciting antiviral immune responses utilizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4249147